Lee S W, Woo S H, Yoo D-S, Park J
Department of Urology, Hanyang University Guri Hospital, Guri, Korea.
Int J Clin Pract. 2014 Feb;68(2):216-21. doi: 10.1111/ijcp.12271. Epub 2013 Dec 22.
Medical expulsive therapy (MET) using alpha-blockers is effective for distal ureteral calculi (UC). We aimed to evaluate the efficacy of tamsulosin for proximal UC expulsion.
An open-label randomized controlled trial was conducted with 108 patients who agreed to conservative management for single, radiopaque, proximal UC ≤ 6 mm and were randomized into group A (n = 54, conservative managements only) or B (n = 54, 0.2 mg tamsulosin once a day). The primary end-point was stone passage rates (SPR) in the intention-to-treat population in 4 treatment weeks. The secondary end-points were estimated in per-protocol population and were time to stone passage, post-trial Euro-quality-of-life (EuroQOL) score, oral analgesic requirements, and willingness to undergo conservative treatment again.
The two groups were well balanced in terms of baseline patient and stone characteristics. Seventy nine patients (73.2%; 35 of group A and 44 of group B) completed the study protocol. The overall SPR was 60.2% (65/108). Group B had a higher SPR (74.1%; 40/54) than group A (46.3%; 25/54; p = 0.003) and a significantly shorter time to stone passage (mean days, A: 19.6 vs. B: 14.3, p = 0.005). The groups did not differ in post-trial EuroQOL score or oral analgesic requirements, whereas 74.3% (26/35) of group A and 90.9% (40/44) of group B were willing to undergo conservative treatment again (p = 0.048). Univariate logistic regression analysis showed that stone size (OR = 1.447, p = 0.045) and tamsulosin treatment (OR = 3.314, p = 0.004) significantly predicted stone expulsion. On multivariate analysis, only tamsulosin was statistically significant (OR=3.198, p = 0.021).
Tamsulosin was associated with significantly higher stone expulsion rate and shorter expulsion time in proximal UC ≤ 6 mm compared with conservative managements only. Our results indicate that similar to patients with distal UC, MET using tamsulosin is a reasonable treatment option for patients with proximal UC.
使用α受体阻滞剂的药物排石疗法(MET)对远端输尿管结石(UC)有效。我们旨在评估坦索罗辛对近端UC排出的疗效。
对108例同意对单个不透X线、近端UC≤6mm进行保守治疗的患者进行了一项开放标签随机对照试验,这些患者被随机分为A组(n = 54,仅进行保守治疗)或B组(n = 54,每天一次0.2mg坦索罗辛)。主要终点是意向性治疗人群在4个治疗周内的结石排出率(SPR)。次要终点在符合方案人群中进行评估,包括结石排出时间、试验后欧洲生活质量(EuroQOL)评分、口服镇痛药需求以及再次接受保守治疗的意愿。
两组在基线患者和结石特征方面平衡良好。79例患者(73.2%;A组35例,B组44例)完成了研究方案。总体SPR为60.2%(65/108)。B组的SPR(74.1%;40/54)高于A组(46.3%;25/54;p = 0.003),结石排出时间显著更短(平均天数,A组:19.6天对B组:14.3天,p = 0.005)。两组在试验后EuroQOL评分或口服镇痛药需求方面无差异,而A组74.3%(26/35)和B组90.9%(40/44)愿意再次接受保守治疗(p = 0.048)。单因素逻辑回归分析显示结石大小(OR = 1.447,p = 0.045)和坦索罗辛治疗(OR = 3.314,p = 0.004)显著预测结石排出。多因素分析显示,只有坦索罗辛具有统计学意义(OR = 3.198,p = 0.021)。
与仅进行保守治疗相比,坦索罗辛在近端UC≤6mm患者中与显著更高的结石排出率和更短的排出时间相关。我们的结果表明,与远端UC患者类似,使用坦索罗辛的MET是近端UC患者的合理治疗选择。